Japan first to approve Avastin in first-line glioblastoma
This article was originally published in Scrip
Executive Summary
The latest batch of approvals in Japan includes Chugai/Roche's Avastin (bevacizumab) for the additional indication of malignant glioma, including recurrent and newly diagnosed glioblastoma.